Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report
ABSTRACT Background Coronavirus disease 2019 (COVID-19) is associated with diffuse
lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing …
lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing …
[HTML][HTML] Moderate hypothermia to treat perinatal asphyxial encephalopathy
DV Azzopardi, B Strohm, AD Edwards… - … England Journal of …, 2009 - Mass Medical Soc
Background Whether hypothermic therapy improves neurodevelopmental outcomes in
newborn infants with asphyxial encephalopathy is uncertain. Methods We performed a …
newborn infants with asphyxial encephalopathy is uncertain. Methods We performed a …
[HTML][HTML] Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the
basis of in vitro activity, preclinical studies, and observational studies. Here, we report the …
basis of in vitro activity, preclinical studies, and observational studies. Here, we report the …
Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data
Objective To determine whether moderate hypothermia after hypoxic-ischaemic
encephalopathy in neonates improves survival and neurological outcome at 18 months of …
encephalopathy in neonates improves survival and neurological outcome at 18 months of …
[HTML][HTML] Donepezil and memantine for moderate-to-severe Alzheimer's disease
Background Clinical trials have shown the benefits of cholinesterase inhibitors for the
treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment …
treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment …
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial
C Ballard, ML Hanney, M Theodoulou… - The Lancet …, 2009 - thelancet.com
Background Data from 12-week placebo-controlled trials have led to mounting concerns
about increased mortality in patients with Alzheimer's disease (AD) who are prescribed …
about increased mortality in patients with Alzheimer's disease (AD) who are prescribed …
[HTML][HTML] Effects of hypothermia for perinatal asphyxia on childhood outcomes
D Azzopardi, B Strohm, N Marlow… - … England Journal of …, 2014 - Mass Medical Soc
Background In the Total Body Hypothermia for Neonatal Encephalopathy Trial (TOBY),
newborns with asphyxial encephalopathy who received hypothermic therapy had improved …
newborns with asphyxial encephalopathy who received hypothermic therapy had improved …
Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial
J Fossey, C Ballard, E Juszczak, I James, N Alder… - Bmj, 2006 - bmj.com
Objective To evaluate the effectiveness of a training and support intervention for nursing
home staff in reducing the proportion of residents with dementia who are prescribed …
home staff in reducing the proportion of residents with dementia who are prescribed …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …